PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
20.45%
R&D growth above 10% signals aggressive investment. Seth Klarman would demand evidence of future payoff potential.
69.30%
G&A growth above 5% signals concerning overhead expansion. Seth Klarman would demand justification for increased costs.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
30.79%
Operating expenses growth above 10% signals concerning cost expansion. Seth Klarman would demand justification.
30.79%
Total costs growth above 5% signals concerning expansion. Seth Klarman would demand justification.
No Data
No Data available this quarter, please select a different quarter.
1.90%
D&A growth 0-5% reflects moderate asset expansion. Benjamin Graham would check if growth drives future value.
-31.40%
Negative EBITDA growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-30.79%
Negative operating income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-10.20%
Negative other expenses growth needs verification. Benjamin Graham would examine sustainability.
-31.28%
Negative pre-tax income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-264.58%
Negative tax expense growth needs verification. Benjamin Graham would examine sustainability.
-31.28%
Negative net income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-21.00%
Negative EPS growth needs thorough analysis. Benjamin Graham would examine operational issues.
-22.22%
Negative diluted EPS growth needs thorough analysis. Benjamin Graham would examine operational issues.
7.78%
Share increase above 2% signals significant dilution. Seth Klarman would demand explanation.
7.68%
Diluted share increase above 2% signals significant dilution. Seth Klarman would demand explanation.